[en] BACKGROUND AND AIMS: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27-83). METHODS: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed. RESULTS: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group. CONCLUSIONS: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Schnitzler, F.
Fidder, H.
Ferrante, M.
Noman, M.
Arijs, I.
Van Assche, G.
Hoffman, I.
Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Vermeire, S.
Rutgeerts, P.
Language :
English
Title :
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
Munkholm P, Langholz E, Davidsen M, at al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
Faubion WA Jr, Loftus EV Jr, Harmsen WS, at al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.
Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998;114:1151-60.
Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996;39:82-6.
Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215-9.
Present DH, Korelitz BI, Wisch N, at al. Treatment of Crohn's disease with 6- mercaptopurine. A long-term, randomized, double-blind study. N Engl J Mad 1980;302:981-7.
Feagan BG, Rochon J, Fedorak RN, at al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Mad 1995;332:292-7.
Feagan BG, Fedorak RN, Irvine EJ, at al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Mad 2000;342:1627-32.
Targan SR, Hanauer SB, Van Deventer SJ, at al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Mad 1997;337:1029-35.
Hanauer SB, Feagan BG, Lichtenstein GR, at al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancat 2002;359:1541-9.
Rutgeerts P, Feagan BG, Lichtenstein GR, at al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroantarology 2004;126:402-13.
Present DH, Rutgeerts P, Targan S, at al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Mad 1999;340:1398-405.
Sands BE, Anderson FH, Bernstein CN, at al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Mad 2004;350:876-85.
Rutgeerts P, Diamond RH, Bala M, at al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointast Endosc 2006;63:433-17.
de Ridder L, Rings EH, Damen GM, at al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowal Dis 2008;14:353-8.
Poupardin C, Lemann M, Gendre JP, at al. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroantarol Clin Biol 2006;30:247-52.
Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008;53:1033-41.
Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroantarol Hapatol 2007;22:1671-7.
Fidder H, Schnitzler F, Ferrante M, at al. Long-term safety of infliximab in the treatment of inflammatory bowel disease: a single center cohort study. J Crohn's Colitis Suppl 2007; 1:3.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.